Evaluation of the mechanism underlying the inhibitory effect of guanidinoacetate on brain Na+, K+-ATPase activity

International Journal of Developmental Neuroscience

Volumn 22, Issue 4, 2004, Pages 191-196

  Zugno, Alexandra I ^a   Franzon, Renata ^a   Chiarani, Fábria ^a   Bavaresco, Caren S ^a   Wannmacher, Clovis M D ^a   Wajner, Moacir ^a   Wyse, Angela T S ^a  

^a FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

Author keywords

Antioxidants; Guanidinoacetate; Hippocampus; L NAME; Na+, K+ ATPase; Rat; Taurine

Indexed keywords

ADENOSINE TRIPHOSPHATASE (MAGNESIUM); ADENOSINE TRIPHOSPHATASE (POTASSIUM SODIUM); GLUTATHIONE; GUANIDINOACETIC ACID; N(G) NITROARGININE METHYL ESTER; TAU PROTEIN; TROLOX C;

ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVITY; HIPPOCAMPUS; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL SIGNIFICANCE; SYNAPTIC MEMBRANE;

ANALYSIS OF VARIANCE; ANIMALS; ANTIOXIDANTS; CA(2+) MG(2+)-ATPASE; CHROMANS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG INTERACTIONS; ENZYME ACTIVATION; ENZYME INHIBITORS; GLUTATHIONE; GLYCINE; GUANIDINOACETATE N-METHYLTRANSFERASE; HIPPOCAMPUS; NA(+)-K(+)-EXCHANGING ATPASE; NG-NITROARGININE METHYL ESTER; RATS; RATS, WISTAR; SYNAPTIC MEMBRANES; TAU PROTEINS; THIOBARBITURIC ACID REACTIVE SUBSTANCES;

EID: 3142598893     PISSN: 07365748     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijdevneu.2004.05.002     Document Type: Article

References (44)

1. +-ATPase activity in synaptosomes from various brain regions. Neurochem. Res. 24:1999;1101-1106
2. Bergamini L., Mutani R., Delsedime M., Durelli L. First clinical experience on the antiepileptic action of taurine. Neurology. 11:1974;261-269
3. Birdsall T.C. Therapeutic applications of taurine. Altern. Med. Rev. 3:1998;128-133
4. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye-binding. Anal. Biochem. 72:1976;248-254
5. 2+-stimulated ATPase activity. Anal. Biochem. 157:1986;375-380
6. Cousin M.A., Nicholls D.G., Pocock J.M. Modulation of ion gradients and glutamate release in cultured cerebellar granule cells by ouabain. J. Neurochem. 64:1995;2097-2104
7. +-ATPase impairment in the retina of diabetic rats. Amino Acids. 23:2002;401-406
8. El-Abhar H.S., Abad El Gawad H. Modulation of cortical nitric oxide synthase, glutamate and redox state by nifedipime and taurine in PTZ-kindled mice. Epilepsia. 44:2003;276-281
9. Erecinska I.A., Silver I.A. Silver, ions and energy in mammalian brain. Prog. Neurobiol. 16:1994;37-71
10. Esterbauer H., Cheeseman K.H. Determination of aldehydic lipid peroxidation products: malonaldehyde and 4-hydroxynonenal. Methods Enzymol. 186:1990;407-421
11. + pump in epilepsy. Ann. Neurol. 16:1984;128-134
12. Henneberry R.L., Novelli A., Cox J.A., Lysko P.G. Neurotoxicity at the N-methyl-D-aspartate receptor in energy-compromised neurons. A hypothesis for cell death in aging and disease. Ann. N.Y. Acad. Sci. 568:1989;225-233
13. Hiramatsu, M., Ohba, S., Edamatsu, R., Kadowari, D., Mori, A., 1992. Effect of guanidino compounds on membrane fluidity of rats synaptosomes. In: De Deyn, P.P., Marescau, I.A., Quereshi, S.D., Mori, A. (Eds.), Guanidino Compounds in Biology & Medicine, vol. 1. John Libbey & Company Ltd., Guildford, UK, pp. 387-393.
14. Huxtable R., Larid H. The prolonged anticonvulsivant action of taurine on genetically determined seizure-susceptibility. Can. J. Neurol. Sci. 5:1978;215-221
15. Jones D.H., Matus A.I. Isolation of plasma synaptic membrane from brain by combination flotation-sedimentation density gradient centrifugation. Biochim. Biophys. Acta. 356:1974;276-287
16. Kendler B.S. Taurine: an overview of its role in preventive medicine. Prev. Med. 18:1989;79-100
17. Lees G.J., Lehmann A., Sandberg M., Hamberg H. The neurotoxicity of ouabain, a sodium-potassium ATPase inhibitor, in the rat hippocampus. Neurosci. Lett. 120:1990;159-162
18. Lees G.J. Contributory mechanisms in the causation of neurodegenerative disorder. Neuroscience. 54:1993;287-322
19. Lees G.J., Leong W. Brain lesions induced by specific and non-specific inhibitors of sodium-potassium ATPase. Brain Res. 649:1995;225-233
20. Leuzzi V., Bianchi M.C., Tosetti M., Carducci C., Cerquiglini C.A., Cioni G., Antonozzi I. Brain creatine depletion: guanidinoacetate methyltransferase deficiency (improving with creatine supplementation). Neurology. 14:2000;1407-1409
21. Marcinkiewicz J., Grabowska A., Bereta J., Stelmaszynska T. Taurine chloramine, a product of activated neutrophils, inhibits in vitro the generation of nitric oxide and other macrophage inflammatory mediators. J. Leukoc. Biol. 58:1995;667-674
22. Matsumoto M., Kobayashi K., Kishikawa H., Mori A. Convulsive activity of methylguanidine in cat and rabbits. IRCS Med. Sci. 4:1976;65
23. +, and strophanthidin in vitro. Neurochem. Res. 14:1989;845-851
24. Mori, A., 1996. Reactive oxygen species and mechanism of induction of seizure by guanidino compounds. In: Parker, L., Hiramatsu, M., Yoshikawa, T. (Eds.), Free Radicals in Brain Physiology and Disorders. Academic press, pp. 3-15.
25. Mori A., Kohno M., Masumizu T., Noda Y., Packer L. Guanidino compounds generate reactive oxygen species. Biochem. Mol. Biol. Int. 40:1996;135-143
26. Moryama T., Nakahama H., Horio M., Yanase M., Orita Y., Kamada T., Kanashoro M., Miyake Y. Decrease in the fluidity of brush-border membrane vesicles induced by gentamicin. A spin labeling study. Biochem. Pharmacol. 38:1989;1169-1174
27. Neu A., Neuhof H., Trube G., Fehr S., Ullrich K., Roeper J., Isbrandt D. Activation of GABA (A) receptors by guanidinoacetate: a novel pathophysiogical mechanism. Neurobiol. Dis. 11:2002;298-307
28. +-ATPase activity due to ozone exposure or cholesterol enrichment. J. Nutr. Sci. Vitaminol. 41:1995;627-634
29. +-ATPase in the brain. Epilepsy. 33:1992;58-64
30. +-ATPase activity from porcine cerebral cortex by NO generating drugs. Brain Res. 704:1995;117-120
31. Schreier S., Polnaze C.F., Smith I.C.P. Spin labels in membrane: problem in practice. Biochem. Biophys. Acta. 553:1978;84-95
32. Schulze A., Ebinger F., Rating D., Mayaetepek E. Improving treatment of guanidinoacetate methyltransferase deficiency: reduction of guanidinoacetic acid in body fluids by arginine restriction and ornithine supplementation. Mol. Genet. Metab. 74:2001;413-419
33. Shiraga H., Hiramatsu M., Mori A. Convulsive activity of α-guanidino glutaric acid and the possible involvement of 5-hydroxytrytamine in the α-guanidino glutaric acid induced seizure mechanism. J. Neurochem. 47:1986;1832-1836
34. +-ATPase activity from cerebral cortex by guanidino compounds accumulating in hyperargininemia. Brain Res. 838:1999;78-84
35. +)-stimulated ATPase and acetylcholonesterase activities of dog brain synaptossomal plasma membranes. Biochem. J. 22:1984;301-307
36. Vianni P., Cervato G., Fiorilli A., Cestaro B. Age-related differences in synaptosomal peroxidative damage and membrane properties. J. Neurochem. 56:1991;253-258
37. Vincent S.R., Hope B.T. Neurons that say NO. Trends Neurosci. 15:1992;108-113
38. Von Figura, K., Hanefeld, F., Isbrandt, D., Stöckler-Ipsiroglu, S., 2001. Guanidinoacetate methyltransferase deficiency. In: Scriver, C.R., Beaudet, A.L., Sly, W.S., Valle, D. (Eds.), The Metabolic and Molecular Bases of Inherited Disease, eighth ed. McGraw-Hill, New York, pp. 1897-1908.
39. +-ATPase activity as a mechanism of neuronal death mediated by concurrent ATP deficiency and oxidant stress. J. Cell Sci. 15:2003;2099-2110
40. +-ATPase activity after brain ischemia. Neurochem. Res. 25:2000;969-973
41. +-ATPase activity in midbrain of rats subjected to arginine administration. Neurochem. Res. 26:2001;515-520
42. Yousef M.I., El Hendy H.A., El-Demesdash F.M., Elagamy E.I. Dietary zinc deficiency induced-changes in the activity of enzymes and the level of free radicals, lipids and protein electrophoretic behavior in growing rats. Toxicology. 175:2002;223-234
43. +-ATPase and membrane fluidity of cerebrocortical membranes after experimental subarachnoid hemorrhage. Neurochem. Res. 16:1993;1033-1039
44. +-ATPase activity in rat striatum by guanidinoacetate. Int. J. Dev. Neurosci. 21:2003;183-189